301 related articles for article (PubMed ID: 32003668)
1. Unveiling the Targets Involved in the Quest of Antileishmanial Leads Using In silico Methods.
Boniface PK; Sano CM; Elizabeth FI
Curr Drug Targets; 2020; 21(7):681-712. PubMed ID: 32003668
[TBL] [Abstract][Full Text] [Related]
2. Repurposing Glyburide as Antileishmanial Agent to Fight Against Leishmaniasis.
Rub A; Shaker K; Kashif M; Arish M; Dukhyil AAB; Alshehri BM; Alaidarous MA; Banawas S; Amir K
Protein Pept Lett; 2019; 26(5):371-376. PubMed ID: 30827222
[TBL] [Abstract][Full Text] [Related]
3. A Systematic Review of Curcumin and its Derivatives as Valuable Sources of Antileishmanial Agents.
Albalawi AE; Alanazi AD; Sharifi I; Ezzatkhah F
Acta Parasitol; 2021 Sep; 66(3):797-811. PubMed ID: 33770343
[TBL] [Abstract][Full Text] [Related]
4. Identification of chalcone-based antileishmanial agents targeting trypanothione reductase.
Ortalli M; Ilari A; Colotti G; De Ionna I; Battista T; Bisi A; Gobbi S; Rampa A; Di Martino RMC; Gentilomi GA; Varani S; Belluti F
Eur J Med Chem; 2018 May; 152():527-541. PubMed ID: 29758517
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of new N-benzyl-1H-benzimidazol-2-amine derivatives against cutaneous, mucocutaneous and visceral Leishmania species.
Nieto-Meneses R; Castillo R; Hernández-Campos A; Maldonado-Rangel A; Matius-Ruiz JB; Trejo-Soto PJ; Nogueda-Torres B; Dea-Ayuela MA; Bolás-Fernández F; Méndez-Cuesta C; Yépez-Mulia L
Exp Parasitol; 2018 Jan; 184():82-89. PubMed ID: 29191699
[TBL] [Abstract][Full Text] [Related]
6. Promising therapeutic targets for antileishmanial drugs.
Werbovetz KA
Expert Opin Ther Targets; 2002 Aug; 6(4):407-22. PubMed ID: 12223057
[TBL] [Abstract][Full Text] [Related]
7. Compounds with potentialities as novel chemotherapeutic agents in leishmaniasis at preclinical level.
González-Matos M; Aguado ME; Izquierdo M; Monzote L; González-Bacerio J
Exp Parasitol; 2024 May; 260():108747. PubMed ID: 38518969
[TBL] [Abstract][Full Text] [Related]
8. The Role of Nitro (NO
Kamdem BP; Elizabeth FI
Curr Drug Targets; 2021; 22(4):379-398. PubMed ID: 33371845
[TBL] [Abstract][Full Text] [Related]
9. Insights about resveratrol analogs against trypanothione reductase of
da Silva AD; Dos Santos JA; Machado PA; Alves LA; Laque LC; de Souza VC; Coimbra ES; Capriles PVSZ
J Biomol Struct Dyn; 2019 Jul; 37(11):2960-2969. PubMed ID: 30058445
[TBL] [Abstract][Full Text] [Related]
10. Rationally Designed Minimal Bioactive Domains of AS-48 Bacteriocin Homologs Possess Potent Antileishmanial Properties.
Corman HN; Ross JN; Fields FR; Shoue DA; McDowell MA; Lee SW
Microbiol Spectr; 2022 Dec; 10(6):e0265822. PubMed ID: 36342284
[TBL] [Abstract][Full Text] [Related]
11. Structure-based virtual screening, molecular docking, ADMET and molecular simulations to develop benzoxaborole analogs as potential inhibitor against Leishmania donovani trypanothione reductase.
Pandey RK; Kumbhar BV; Sundar S; Kunwar A; Prajapati VK
J Recept Signal Transduct Res; 2017 Feb; 37(1):60-70. PubMed ID: 27147242
[TBL] [Abstract][Full Text] [Related]
12. Targeting pteridine reductase 1 and dihydrofolate reductase: the old is a new trend for leishmaniasis drug discovery.
das Neves GM; Kagami LP; Gonçalves IL; Eifler-Lima VL
Future Med Chem; 2019 Aug; 11(16):2107-2130. PubMed ID: 31370699
[TBL] [Abstract][Full Text] [Related]
13. Recent patents in the treatment and prevention of leishmaniasis.
Shahid SK
Pharm Pat Anal; 2023 Sep; 12(5):237-248. PubMed ID: 38063376
[TBL] [Abstract][Full Text] [Related]
14. Screening natural products database for identification of potential antileishmanial chemotherapeutic agents.
Venkatesan SK; Saudagar P; Shukla AK; Dubey VK
Interdiscip Sci; 2011 Sep; 3(3):217-31. PubMed ID: 21956744
[TBL] [Abstract][Full Text] [Related]
15. In-silico analyses of sesquiterpene-related compounds on selected Leishmania enzyme-based targets.
Bernal FA; Coy-Barrera E
Molecules; 2014 Apr; 19(5):5550-69. PubMed ID: 24786692
[TBL] [Abstract][Full Text] [Related]
16. Structural insights into the enzymes of the trypanothione pathway: targets for antileishmaniasis drugs.
Colotti G; Baiocco P; Fiorillo A; Boffi A; Poser E; Chiaro FD; Ilari A
Future Med Chem; 2013 Oct; 5(15):1861-75. PubMed ID: 24144416
[TBL] [Abstract][Full Text] [Related]
17. Application of nanotechnology in treatment of leishmaniasis: A Review.
Akbari M; Oryan A; Hatam G
Acta Trop; 2017 Aug; 172():86-90. PubMed ID: 28460833
[TBL] [Abstract][Full Text] [Related]
18. Antimicrobial peptides for leishmaniasis.
Cobb SL; Denny PW
Curr Opin Investig Drugs; 2010 Aug; 11(8):868-75. PubMed ID: 20721829
[TBL] [Abstract][Full Text] [Related]
19. Promising Molecular Targets Related to Polyamine Biosynthesis in Drug Discovery against Leishmaniasis.
Santiago-Silva KM; Camargo PG; Bispo MLF
Med Chem; 2022; 19(1):2-9. PubMed ID: 35838221
[TBL] [Abstract][Full Text] [Related]
20. Some Scaffolds as Anti-leishmanial Agents: A Review.
Mahender T; Pankaj W; Kumar SP; Ankur V; Kumar SS
Mini Rev Med Chem; 2022; 22(5):743-757. PubMed ID: 34517799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
